Report Overview:
The Asia Pacific pharmaceutical grade ethanol market is experiencing steady growth, driven by the expanding pharmaceutical industry and increasing healthcare investments. China accounts for 40% of the market, followed by India at 30% and Japan at 20%. In 2023, the pharmaceutical manufacturing sector consumed 70% of total production, with antiseptics and disinfectants at 20% and vaccine production at 10%. The market saw a 15% increase in demand due to the COVID-19 pandemic and vaccine production efforts. Key players include Godavari Biorefineries Ltd. (India) and Greenfield Global Inc. (Canada), holding a combined 35% market share in the region. The industry is investing in advanced purification technologies, with a 10% increase in R&D spending on continuous distillation processes in 2023. Challenges include volatile raw material prices and strict regulatory compliance, leading to an 8% rise in production costs. The trend towards biopharmaceuticals has driven a 12% growth in ethanol demand for protein purification processes. The market is benefiting from the expansion of contract manufacturing organizations (CMOs) in the region, with a 20% increase in pharmaceutical grade ethanol consumption by CMOs for various drug formulations.
Market Value:
The Asia Pacific Pharmaceutical Grade Ethanol market size was valued at US$ 0.87 million in 2024 and is projected to reach US$ 1.16 billion by 2030, at a CAGR of 4.9% during the forecast period 2024-2030. CAGR of 4.9%
(2022 – 2029)
By Types:
Low Purity
High Purity
By Applications:
Pharmaceutical and Medical
Personal Care & Cosmetic
Key players include:
•Zhejiang Huayi Pharmaceutical Co., Ltd.
•Jiangsu Hengrui Medicine Co., Ltd.
•Shanghai Industrial United Holdings Co., Ltd.
•Mitsubishi Chemical Corporation
•LG Chem Ltd.
•Godavari Biorefineries Ltd.
•Including or Excluding key companies relevant to your analysis.
